Zoetis (ZTS) announced that Health Canada has approved Portela for the alleviation of pain associated with osteoarthritis in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor, which is a mediator of OA pain and inflammation.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZTS:
- Zoetis Positioned for Long-Term Growth with Strategic Market Expansion and Innovative Product Launches
- Zoetis: Strong Innovation Pipeline and Attractive Valuation Justify Buy Rating Despite Near-Term Challenges
- Zoetis Hosts Innovation Webcast on Animal Health
- Zoetis receives Lenivia EC marketing authorization for osteoarthritis in dogs
- Zoetis: Buy Rating Affirmed Amidst Challenges and Growth Prospects